STA,ANA Hospital, one of the Manila City's s six public hospitals, will be participating in the clinical trials on the effectivity of the “Avigan” drug in the treatment of the coronavirus disease 2019 (Covid-19).
Manila Mayor Francisco ‘Isko Moreno’ Domagoso said on his Facebook page on Tuesday that 1,300 tablets of the Japanese anti-flu drug “Avigan” were delivered to Sta. Ana Hospital.
The drugs came from the Department of Health (DOH).
Domagoso said Sta. Ana Hospital “is among the facilities who will conduct clinical trials using the anti-flu drug for Covid-19 patients”.
Sta. Ana Hospital is one of the four hospitals nationwide which will participate in the 90-day clinical trial to test if the said drugs can effectively treat Covid-19 patients.
The Manila Public Information Office said the national government spent about PHP18 million to be able to conduct the clinical trial here in the country.
Meanwhile, Sta. Ana Hospital also received on Friday a new Polymerase Chain Reaction (PCR) swab testing machine from the Department of Budget and Management (DBM).
The PCR testing machine will be used for the new molecular laboratory which will be built in the hospital.
To further strengthen the city’s fight against the pandemic, a new serology testing machine has been received by Ospital ng Tondo.
The machine will be used for the third Covid-19 walk-in testing center of the city.
Ospital ng Tondo is currently closed for new patients after Domagoso granted the request of the hospital administration to temporarily close after 32 of its health care workers tested positive for Covid-19.
On Monday, misting and disinfecting gates were installed at the Quirino Grandstand where the second Covid-19 drive-thru testing center of the city is located.
“This is still part of the city government of Manila’s continuous action to contain and delay the further spread of Covid-19 and to make sure that the health of every individual who falls in line to have themselves tested at our drive-thru testing center is safe,” Domagoso said in his post. (By Marita Moaje)
No comments:
Post a Comment